SUN.L

Surgical Innovations Group Plc
Surgical Innovations - Notice of Results
10th September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4950D
Surgical Innovations Group PLC
10 September 2024
 

 

Surgical Innovations Group plc

("Surgical Innovations", the "Company", or the "Group")

 

Notice of Interim Results

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces it will release its interim results for the six months ended 30 June 2024, on Monday 30 September 2024.

 

Investor briefing

David Marsh, Chief Executive Officer, and Chris Martin, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on 30 September 2024 at 4:00 p.m. BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00 a.m. the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet Surgical Innovations Group plc via:

 

https://www.investormeetcompany.com/surgical-innovations-group-plc/register-investor

 

Investors who already follow Surgical Innovations Group plc on the Investor Meet Company platform will automatically be invited.

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Chris Martin, CFO

Tel: 0113 230 7597

 

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Alex Bond / Oliver Platts

 


 

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Charlotte Edgar

Mob: 07980 541 893 / 07884 664 686

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs,the Company's Reposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.

 

Further information

Further details of the Group's businesses and products are available on the following websites:

 

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

 

To receive regular updates by email, please contact si@walbrookpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORDZGGLVLKGDZM]]>
TwitterFacebookLinkedIn